Company: NCEL
Filing Date: 2025-06-09
Form Type: F-4/A
Source: 0001213900-25-052354
Chunk: 411

Company: NewcelX Ltd.
Filing Date: 2025-06-09
Form: F-4/A
Chunk 411
---
 a registered direct offering of 7,000,000 NLS Common Shares, at a purchase price of $0.25 per share. The offering closed on March22, 2024. In addition, pursuant to the March Purchase Agreement, the investors received unregistered warrants, or the Common Warrants, to purchase up to an aggregate of 3,500,000 NLS Common Shares at an exercise of $0.25 per share in a concurrent private placement. The Common Warrants were immediately exercisable upon issuance and will expire five years following the date of issuance. The March Purchase Agreement contains customary representations and warranties and agreements of the Company and the investors and customary indemnification rights and obligations of the parties. Pursuant to the March Purchase Agreement, we agreed not to enter into any agreement to issue or announce the issuance or proposed issuance of any NLS Common Shares or NLS Common Share equivalents for a period of 45 days following the closing of the offering, subject to certain customary exceptions. We have also agreed that from the date of the March Purchase Agreement until one year after the closing date of the offering, we shall not enter into an agreement to effect any issuance by us or any of our subsidiaries of NLS Common Shares or NLS Common Share equivalents (or a combination of units thereof) involving a variable rate transaction. The offering resulted in gross proceeds to us of $1,750,000. NLS intends to use the net proceeds from the offering for working capital and general corporate purposes. On June 28, 2024, we entered into a securities purchase agreement providing for the issuance in a registered direct offering of 81,944 NLS Common Shares at a purchase price of $9.60 per share. In addition, the investors in the offering received unregistered warrants to purchase up to an aggregate of 81,944 NLS Common Shares at an exercise of $9.60 per share in a concurrent private placement. The common warrants were immediately exercisable upon issuance and expire five years following the date of issuance. The agreement includes customary representations, warranties, and indemnification provisions. We agreed not to issue or announce the issuance of any NLS Common Shares or equivalents for 15 days post -closing, with certain exceptions, and not to engage in variable rate transactions for one -yearpost -closing. The offering generated gross proceeds of approximately $786,660. 230 On September 16, 2024, we entered into a warrant amendment agreement with an institutional investor to amend warrants to purchase up to 172